CSIMarket Company Name, Ticker, Customers, else..
 
Cell Source Inc   (CLCS)
Other Ticker:  
 
 
Price: $0.2980 $-0.02 -6.875%
Day's High: $0.32 Week Perf: -0.33 %
Day's Low: $ 0.23 30 Day Perf: 23.65 %
Volume (M): 0 52 Wk High: $ 0.84
Volume (M$): $ 0 52 Wk Avg: $0.40
Open: $0.27 52 Wk Low: $0.00



 Market Capitalization (Millions $) 13
 Shares Outstanding (Millions) 42
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Cell Source Inc
Cell Source Inc is a biotechnology company that specializes in the development and production of human cell therapies for the treatment of various diseases. The company utilizes advanced technologies and proprietary processes to manufacture high-quality, functional cells that are used in regenerative medicine and immunotherapy applications. Cell Source Inc aims to improve patient outcomes and revolutionize the field of cell-based therapies through its innovative research and development efforts.


   Company Address: 57 West 57th Street New York 10019 NY
   Company Phone Number: 416-7896   Stock Exchange / Ticker: CLCS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY      % 
APLS      % 
ME   -16.95%    
SPRO   -16.95%    
UTHR   -16.95%    
WVE        22.33% 
• View Complete Report
   



Cell Source Inc

Cell Source Inc Delights Shareholders with Substantial Gain and Promising Operating Deficit Reduction in Q2 of 2023 Earnings Season

Investors Remain Watchful as Cell Source Inc Maneuvers Operating Deficit During Recent Earnings Season
In the latest earnings season that spanned from April to June 30, 2023, Cell Source Inc, the renowned Major Pharmaceutical Preparations company, experienced a lack of significant improvements in its top-line performance. However, investors closely monitored the company's operating deficit, which stood at $-0.905465 million during this period. This figure, although representing a deficit, overshadowed the corresponding timeframe in the previous fiscal year ending June 30, 2022. Given Cell Source Inc's focus on research and development activities, this outcome was largely anticipated.
Throughout the second quarter of the 2023 earnings season, Cell Source Inc's executives demonstrated more efficient management, successfully reducing the deficit to $-1.242 million. This positive development has provided some reassurance to investors, indicating that the company's efforts to improve its financial performance are gaining traction. Nevertheless, maintaining a watchful eye on the company's future performance remains crucial.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com